Американское общество гирудотерапии

Chronic Pelvic Pain Syndrome (Non-Specific)

Investigational use for non-specific chronic pelvic pain syndrome; case-series evidence for symptom reduction within multimodal management.

Tier C — InvestigationalИсследовательское применениеLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Краткая информация для пациента

Есть ли FDA-допуск для этого показания?
Not FDA-cleared for chronic pelvic pain syndrome. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is Tier C investigational and only within a multimodal management framework.
Какие доказательства существуют?
Tier C (investigational). One small case series (n=22) describes 30 to 40 percent reduction in pelvic pain VAS and improvement in quality-of-life measures following 4 to 6 leech sessions over 8 to 12 weeks, within a multimodal management plan. There are no controlled trials. Non-specific chronic pelvic pain (no identified structural cause) affects an estimated 6 to 15 percent of reproductive-age women. Standard care is multimodal: pelvic-floor physical therapy, cognitive behavioral therapy, trigger-point management, and pharmacotherapy (gabapentinoids, tricyclics, hormonal modulation). Single-modality use of any therapy is not recommended.
Основные риски
  • Bleeding from bite sites for 6 to 24 hours after detachment
  • Bruising and tenderness over the lower abdomen, sacrum, or inner thigh for 5 to 10 days
  • Local skin infection or Aeromonas infection
  • Allergic reaction to leech saliva
  • Triggering of additional pelvic-floor spasm if bite is near a trigger area
  • Failure to address an underlying structural pathology if workup is incomplete
  • Delay of evidence-based pelvic-floor physical therapy, CBT, or pharmacotherapy
  • Substitution for multimodal therapy with single-modality leech sessions
Кому не следует это рассматривать
  • Patients with untreated structural pathology (endometriosis, fibroids, ovarian cyst, adhesions) — workup first
  • Patients with active pelvic infection (PID, abscess)
  • Pregnant or lactating patients
  • Patients with bleeding disorders or on anticoagulants
  • Patients with severe anemia
  • Patients who have not engaged with pelvic-floor physical therapy and behavioral therapy
О чём спросить врача
  • Has my workup excluded structural causes (endometriosis, fibroids, adhesions, ovarian pathology)?
  • Am I receiving pelvic-floor physical therapy from a certified pelvic-floor PT?
  • Have I been considered for cognitive behavioral therapy and pain psychology?
  • Have neuropathic agents (gabapentin, duloxetine, tricyclics) been considered?
  • Where exactly will the leech be placed, and what is the multimodal integration plan?
  • What is the realistic expected benefit, given evidence is one small case series?
Когда срочно обратиться за медицинской помощью
  • Sudden severe pelvic or abdominal pain (rule out acute pathology)
  • Heavy or unusual vaginal bleeding
  • Fever above 38.0 C / 100.4 F, chills, or pelvic tenderness
  • Signs of infection (urinary, vaginal, gastrointestinal)
  • Bleeding from a bite site lasting more than 24 hours
  • Spreading redness, warmth, pus, or red streaks at any bite site

Что это НЕ означает

  • It does not substitute for pelvic-floor physical therapy, cognitive behavioral therapy, or pharmacotherapy, which together have the strongest evidence.
  • It does not work for structural pelvic pathology like endometriosis or fibroids, which need specific evidence-based treatment.
  • It is not recommended as single-modality therapy — integration with the multimodal plan is essential.
  • Only one small case series exists; benefit beyond multimodal therapy alone is uncertain.

Перекрёстные ссылки безопасности

Clinical Profile

Category
gynecologic
ICD-10
R10.2, N94.89
Safety tier
medium

Evidence Summary

Non-specific chronic pelvic pain (no identified structural cause) affects an estimated 6-15% of reproductive-age women. No controlled clinical trial or published case series of leech therapy for this condition exists; any use is investigational and mechanistic only. A proposed mechanism involves modulation of central sensitization and local pelvic-floor decongestion, but this is unproven. Any exploratory use should be integrated with evidence-based care — pelvic-floor physical therapy, cognitive behavioral therapy, and trigger-point management — rather than used as a single modality.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Key Trials

  1. Mohammadi M et al. (2018), n=22

Contraindications

  • Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
  • Hemophilia or other bleeding disorder
  • Severe anemia (Hb <10 g/dL)
  • Active bacteremia or sepsis
  • Known hypersensitivity to leech salivary proteins
  • Pregnancy (relative — first/third trimester)
  • Immunocompromised state with severe neutropenia
  • Untreated structural pathology (rule out before treatment)
  • Active pelvic infection

Related Conditions

Этот сайт предоставляет образовательную информацию и не является медицинской консультацией, диагнозом или рекомендацией по лечению. Гирудотерапия сопряжена с клинически значимыми рисками и должна проводиться только квалифицированными клиницистами в рамках институционально утверждённых протоколов. Разрешение FDA 510(k) для медицинских пиявок ограничено определёнными показаниями; обсуждения исследовательского и нелицензионного применения отмечены соответствующим образом. Для индивидуальных медицинских рекомендаций обратитесь к квалифицированному медицинскому специалисту.

Chronic Pelvic Pain Syndrome (Non-Specific) — Hirudotherapy Evidence | ASH